Literature DB >> 16293847

Adjuvant trastuzumab for breast cancer: an increasingly common ethical and economic conundrum.

Matthew L Grove.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16293847      PMCID: PMC1285140          DOI: 10.1136/bmj.331.7526.1202-b

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  2 in total

1.  Adjuvant trastuzumab for breast cancer.

Authors:  Rebecca Dent; Mark Clemons
Journal:  BMJ       Date:  2005-11-05

2.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

  2 in total
  1 in total

1.  Media Hyping and the "Herceptin Access Story": An Analysis of Canadian and UK Newspaper Coverage.

Authors:  Julia Abelson; Patricia A Collins
Journal:  Healthc Policy       Date:  2009-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.